Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - ASSEMBLY BIOSCIENCES, INC. | v245449_ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 13, 2012
|
VENTRUS BIOSCIENCES, INC.
|
||
|
(Exact name of registrant as specified in its charter)
|
|
Delaware
|
001-35005
|
20-8729264
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer ID Number)
|
|
99 Hudson Street, 5th Floor, New York, New York
|
10013
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
Registrant’s telephone number, including area code
|
(646) 706-5208
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 8.01. Other Events.
On January 13, 2012, Ventrus Biosciences, Inc. issued a press release announcing the publication of the prior phase 2b study for iferanserin (VEN 309) for the treatment of hemorrhoid disease, in the peer reviewed journal Clinical Therapeutics. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit No.
|
Description
|
|
|
99.1
|
Press release dated January 13, 2012.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
VENTRUS BIOSCIENCES, INC.
|
|||
|
Date: January 13, 2012
|
By:
|
/s/ David J. Barrett | |
| David J. Barrett, Chief Financial Officer | |||